This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): morphine sulfate extended-release, Kapanol, Morcap SR
Description: Kadian is a long-acting (once or twice daily) formulation of the opioid analgesic morphine. Morphine produces both its therapeutics effects and its adverse effects by interaction with one or more classes of specific opioid receptors located throughout the body. Morphine acts as a pure agonist, binding with and activating opioid receptors at sites in brain and the spinal cord to produce analgesia.
Kadian was originally developed and launched by Faulding (a subsidiary of Mayne), and now marketed by Actavis, a subsidiary of Watson Pharmaceuticals (now Actavis).
King and Alpharma
In September 2008, King Pharmaceuticals announced that it commenced a tender offer, through a wholly owned subsidiary, to acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37 per share in cash. The deal was unanimously rejected by Alpharma's board on September 26, 2008.
In November 2008, King Pharmaceuticals and Alpharma announced that the two companies signed a definitive merger agreement under which King will acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37.00 per share in cash for a total equity value of approximately $1.6 billion.
In December 2008, King completed its acquisition of Alpharma.
King and Activis
In connection with the proposed consent, King entered into an asset purchase agreement with...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: